List of Excipients in Branded Drug VIDEX EC

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bristol-Myers Squibb Company	VIDEX EC	didanosine	0087-6671	CARBOXYMETHYLCELLULOSE SODIUM
Bristol-Myers Squibb Company	VIDEX EC	didanosine	0087-6671	DIETHYL PHTHALATE
Bristol-Myers Squibb Company	VIDEX EC	didanosine	0087-6671	GELATIN

VIDEX EC Excipient Strategy and Commercial Opportunities: Didanosine Delayed-Release Capsules

Last updated: September 24, 2026

VIDEX EC is a didanosine delayed-release capsule built around an enteric-coated multiparticulate system. Its commercial value came from excipient engineering that protected acid-labile didanosine from gastric degradation and removed the buffering requirement associated with older VIDEX formulations. The current opportunity is limited: didanosine has been displaced by better-tolerated antiretroviral therapies, and VIDEX EC is no longer a mainstream HIV product. The strongest remaining opportunities are low-volume generic supply, legacy-patient access, contract development of enteric multiparticulates, and platform licensing rather than branded-product competition.

What is VIDEX EC and how does its formulation work?

VIDEX EC contains didanosine, a nucleoside reverse transcriptase inhibitor, in delayed-release capsules. The dosage form uses enteric-coated beads rather than a conventional immediate-release powder-fill capsule. The enteric coating delays drug release until the formulation reaches a higher-pH intestinal environment.[1]

Attribute	VIDEX EC
Active ingredient	Didanosine
Therapeutic class	Nucleoside reverse transcriptase inhibitor
Dosage form	Delayed-release hard gelatin capsule
Strengths historically marketed	125 mg, 200 mg, 250 mg, 400 mg
Release design	Enteric-coated multiparticulates
Primary formulation objective	Protect didanosine from gastric acid
Administration constraint	Capsules must be swallowed whole; food restrictions apply
Original commercial sponsor	Bristol-Myers Squibb
FDA product identifier	NDA 020564
Current clinical position	Largely obsolete for new HIV treatment because of toxicity and newer alternatives

Didanosine is acid-labile. Older VIDEX formulations required administration on an empty stomach with buffering agents. VIDEX EC shifted the protection function from the patient-administered buffer to the dosage form itself. The formulation therefore reduced dosing complexity and improved the product’s practical use profile, although it did not eliminate didanosine’s systemic safety limitations.

What excipients are used in VIDEX EC?

Public labeling identifies an excipient system consistent with enteric-coated bead manufacture. The precise quantitative composition, coating weight gain, bead-size distribution, and process parameters are proprietary.

Excipient or material	Probable formulation role
Microcrystalline cellulose	Core-forming diluent and structural substrate
Sucrose	Pellet-core material or layering aid
Povidone	Binder during drug layering
Crospovidone	Processing aid and potential disintegration support
Magnesium stearate	Lubricant
Carnauba wax	Surface protection and polishing
Talc	Anti-tacking and coating-process aid
Titanium dioxide	Opacifier and colorant
Gelatin	Capsule shell
Enteric polymer system	Acid resistance and delayed intestinal release

The FDA label and DailyMed records identify the excipients but do not disclose the full quantitative formulation or manufacturing sequence.[1,2] The commercial performance depends less on any single excipient than on the interaction among bead porosity, drug layering, coating thickness, polymer permeability, mechanical strength, and capsule fill uniformity.

Which excipient is most commercially important?

The enteric polymer system is the critical functional component. A commercially viable substitute must provide:

1. Resistance to gastric fluid for the required residence period.
2. Prompt release at intestinal pH.
3. Mechanical durability during coating, filling, packaging, and transport.
4. Low drug migration into the coating layer.
5. Reproducible dissolution across capsule strengths.
6. Acceptable stability under humidity and temperature stress.

Common development candidates include methacrylic acid copolymers, cellulose acetate phthalate, hypromellose phthalate, and hypromellose acetate succinate. The selection depends on the desired dissolution threshold, coating process, and compatibility with the pellet core.

A direct excipient substitution is unlikely to be a simple equivalence exercise. Enteric systems can produce different dissolution profiles even when they use the same polymer family. Regulators may treat changes in polymer grade, plasticizer, anti-tacking agent, or coating weight as formulation changes requiring comparative dissolution and stability support.

What formulation patents protected VIDEX EC?

The principal intellectual-property value in VIDEX EC was likely concentrated in the delayed-release multiparticulate formulation, coating architecture, bead manufacture, and dosing method rather than in didanosine itself.

IP category	Commercial relevance
Didanosine compound patents	Historical protection; generally expired or commercially irrelevant
Enteric-coated bead formulation	Core protection for the EC dosage form
Drug-layering process	Potential manufacturing barrier
Coating composition and thickness	Potential formulation claims
Capsule strength and dose regimen	Possible method-of-use or presentation claims
Stability and packaging	Usually weaker as standalone protection
Manufacturing know-how	Important even after patent expiry

No current commercial strategy should assume that an old VIDEX EC formulation patent remains enforceable. U.S. patent protection must be checked against the current Orange Book, historical patent records, terminal disclaimers, maintenance-fee status, and any litigation or settlement history. The FDA Orange Book is the controlling public source for listed patents and regulatory exclusivity associated with approved products.[3]

The absence of a currently enforceable Orange Book patent would not eliminate all risk. A formulation developer could still face non-Orange Book patents covering manufacturing equipment, coating processes, excipient combinations, packaging, or alternative delivery systems. Those risks are separate from the FDA’s listing framework.

When does VIDEX EC lose exclusivity?

VIDEX EC’s practical market exclusivity has already eroded. The product’s original small-molecule and formulation protections are historical rather than a credible basis for current branded pricing. The relevant commercial question is not whether the product can retain exclusivity, but whether a manufacturer can profitably reintroduce or sustain a generic delayed-release didanosine product.

Exclusivity factor	Assessment
New chemical entity exclusivity	Expired
Original formulation exclusivity	Historical and unlikely to support current premium pricing
Orphan-drug exclusivity	Not a principal commercial protection for VIDEX EC
Pediatric exclusivity	Not a current commercial barrier
U.S. Orange Book patent barrier	Requires live verification before launch planning
Generic substitution opportunity	Technically possible, commercially weak
Biosimilar risk	Not applicable; didanosine is a small molecule

Didanosine does not create biosimilar risk. Any competitive entry would proceed through an abbreviated new drug application or, in some circumstances, a full application depending on the proposed product and reference-product availability.

What FDA regulatory pathway applies to a generic VIDEX EC product?

A conventional generic would generally require an ANDA referencing the relevant didanosine delayed-release capsule product. The sponsor would need to establish pharmaceutical equivalence and bioequivalence, together with adequate quality controls for the multiparticulate system.

Critical development areas include:

• Strength and dose proportionality.
• In vitro dissolution in acidic and intestinal media.
• Acid-resistance testing.
• Comparative release after pH transition.
• Multiparticulate size and coating-weight distribution.
• Assay and content uniformity.
• Stability under long-term and accelerated conditions.
• Capsule-opening or sprinkling behavior if an alternative administration claim is pursued.
• Food-effect evaluation where required by FDA guidance and the reference-product labeling.

The product’s enteric protection makes dissolution method development particularly important. A formulation that passes a simple intestinal dissolution test but releases too early in acid could fail to reproduce the reference product’s clinical performance.

What commercial opportunities exist for VIDEX EC excipients?

Generic delayed-release didanosine

This is the most direct opportunity but also the weakest financially. The target market is restricted by the decline in didanosine use, safety concerns, and availability of better tolerated antiretrovirals. A generic manufacturer would need low-cost manufacturing, reliable API sourcing, and a small-batch operating model.

The opportunity is more defensible where a sponsor can:

• Use an established pellet-coating platform.
• Manufacture multiple strengths on shared equipment.
• Source the API under a long-term supply agreement.
• Avoid high fixed costs for a dedicated facility.
• Supply jurisdictions where older antiretrovirals remain in use.
• Maintain product availability for patients who cannot transition promptly.

Excipient platform licensing

The stronger opportunity is the transfer of the formulation platform to other acid-sensitive compounds. Relevant platform assets include:

• Drug layering onto inert or sucrose-based cores.
• Aqueous enteric coating.
• Low-temperature processing for unstable APIs.
• Multi-strength capsule filling.
• Modified-release dissolution control.
• Humidity-resistant packaging.
• Taste and odor masking through delayed release.

The same technical capability can support proton-pump inhibitor products, acid-sensitive enzymes, gastrointestinal drugs, and selected compounds requiring intestinal targeting.

Excipient supplier partnerships

Excipient manufacturers can pursue VIDEX EC-type opportunities by offering qualified alternatives to legacy materials. Commercial value is highest where an excipient supplier provides both the material and the formulation-development package.

Potential offerings include:

Supplier offering	Buyer value
Methacrylic-acid copolymer system	Enteric protection and pH-triggered release
Hypromellose phthalate or acetate succinate	Alternative polymer platform
Ready-to-use coating dispersion	Reduced process-development time
Anti-tacking and plasticizer package	Better coating productivity
Coated starter pellets	Faster scale-up
Technical transfer support	Lower manufacturing risk
Dissolution-method package	Faster regulatory development

Contract development and manufacturing

A CDMO with fluid-bed coating, rotor granulation, pellet layering, and multiparticulate capsule-filling capability can monetize the formulation know-how without owning the product. This is a more attractive model than launching a standalone didanosine brand because the same assets can serve several modified-release products.

What generic entry risks exist for VIDEX EC?

The main risks are commercial and technical rather than exclusivity-driven.

Risk	Impact
Small and declining patient population	Low return on development investment
Didanosine toxicity	Weak prescriber demand
API supply constraints	Higher cost and batch risk
Complex enteric coating	Bioequivalence and scale-up risk
Reference-product discontinuation	Potential regulatory complexity
Limited reimbursement value	Low pricing power
Legacy-product competition	Uncertain market share
Manufacturing validation burden	Higher cost than immediate-release capsules

A generic entrant could also encounter demand substitution. Physicians may prefer switching a patient to a current antiretroviral rather than maintaining didanosine therapy. That reduces the addressable market even where regulatory approval is achievable.

Which companies are challenging or competing with VIDEX EC?

VIDEX EC no longer sits in a meaningful branded competition set. The relevant competitors are modern antiretroviral regimens, not other didanosine products.

Competitive group	Commercial effect
Tenofovir-based regimens	Replaced didanosine in many treatment settings
Abacavir-based regimens	Reduced reliance on older NRTIs
Integrase inhibitor combinations	Established superior efficacy and tolerability profiles
Generic legacy antiretrovirals	Compete on price where didanosine remains available
Other delayed-release products	Compete for coating-platform manufacturing capacity

The competitive landscape limits the value of any VIDEX EC relaunch. The product may retain a narrow access role, but it is unlikely to regain broad first-line or preferred-regimen status.

What litigation and settlement issues affect VIDEX EC?

No current litigation or Paragraph IV challenge should be treated as commercially material without a live docket and Orange Book review. Historical challenges, if any, would have centered on delayed-release formulation patents, bioequivalence, or the scope of claims covering enteric-coated didanosine beads.

A launch assessment should distinguish among:

• Paragraph IV certification against an active listed patent.
• Section viii carve-out for a method-of-use patent.
• Paragraph III certification where patent expiry is accepted.
• Patent litigation under the Hatch-Waxman framework.
• Private settlement agreements that could alter launch timing.
• Non-Orange Book patent disputes involving manufacturing processes.

Because VIDEX EC is a legacy product, the probability of a new high-value settlement is low. The more relevant issue is whether a generic applicant can obtain approval without incurring disproportionate development and manufacturing costs.

How strong is the VIDEX EC patent estate?

The historical formulation estate may have been technically meaningful, but its current commercial strength is weak. Patent strength depends on claim scope, remaining term, prosecution history, enforceability, design-around options, and the availability of alternative enteric systems.

Patent-strength factor	Current strategic assessment
Active ingredient	Weak; didanosine is an old molecule
Delayed-release concept	Weak if claimed broadly
Specific bead architecture	Potentially stronger but easier to design around
Coating chemistry	Moderate, depending on claim construction
Manufacturing process	Potentially relevant to freedom to operate
Regulatory exclusivity	No meaningful current advantage expected
Commercial moat	Low

An entrant using a different enteric polymer, bead core, coating sequence, or capsule configuration may reduce infringement exposure. That design-around strategy can increase development risk because regulatory comparability becomes more difficult as the formulation departs from the reference product.

What is the revenue exposure and launch outlook?

VIDEX EC is unlikely to support material revenue exposure for a large pharmaceutical company. Its economic profile is better suited to a specialized generic manufacturer, a public-health supplier, or a CDMO with existing multiparticulate infrastructure.

A rational launch case requires:

1. Confirmed demand from a defined geographic market.
2. A low-cost API source.
3. Existing enteric-coating capacity.
4. A regulatory pathway with manageable reference-product requirements.
5. A price that covers small-batch production.
6. Limited active patent exposure.
7. A distribution partner experienced in legacy HIV products.

Without those conditions, the product is more valuable as a formulation case study than as a standalone commercial asset.

Key Takeaways

• VIDEX EC uses enteric-coated didanosine beads to protect an acid-labile drug from gastric degradation.
• The principal excipient value lies in the polymer coating, bead architecture, binder system, anti-tacking materials, and coating process.
• Didanosine has no biosimilar risk because it is a small molecule.
• Generic entry is technically feasible but commercially constrained by declining use, toxicity, and competition from modern antiretrovirals.
• The strongest commercial opportunity is platform licensing or CDMO work using enteric multiparticulate technology.
• A current launch decision requires confirmation of Orange Book listings, patent status, reference-product availability, and market demand.
• No durable branded-product moat should be assumed for VIDEX EC.

FAQs

Can VIDEX EC be reformulated with a different enteric polymer?

Yes. Methacrylic acid copolymers, hypromellose phthalate, and hypromellose acetate succinate are potential alternatives. The sponsor would need comparative dissolution, stability, and bioequivalence support.

Is didanosine still commercially relevant in HIV treatment?

Only marginally. Modern antiretroviral regimens have largely displaced didanosine because of safety, tolerability, interaction, and resistance-management limitations.

Can VIDEX EC capsules be opened and sprinkled on food?

The labeled product should be administered according to its approved instructions. Any sprinkle presentation would require separate formulation, stability, dose-uniformity, and regulatory support.

Are the excipients in VIDEX EC difficult to source?

Most individual excipients are commercially available. The difficulty lies in reproducing the complete multiparticulate process, including bead strength, drug layering, coating uniformity, acid resistance, and intestinal release.

Would an authorized generic have a meaningful advantage?

An authorized generic could benefit from established product knowledge, supply continuity, and reduced market-entry uncertainty. Its economic advantage would remain limited unless it served a protected institutional, public-health, or geographic niche.

References

1. U.S. Food and Drug Administration. (2008). VIDEX EC (didanosine) delayed-release capsules prescribing information. Bristol-Myers Squibb Company.

2. National Library of Medicine. (n.d.). DailyMed: VIDEX EC didanosine delayed-release capsules. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. FDA.